microbiota

Stachyose hydrate is a natual product,it highly promotes proliferation of lactic acid bacteria (LAB) by inducing LAB to produce more α-galactosidase to hydrolyze stachyose.

Methyl 2-hydroxy-4-methylvalerate [Methyl 2-hydroxyisovalerate] is a predominant volatile compound found in Zhenjiang aromatic vinegar.

Carbendazim (Mercarzole) is a broad-spectrum benzimidazole antifungal with potential antimitotic and antineoplastic activities. Although the exact mechanism of action is unclear, carbendazim appears to binds to an unspecified site on tubulin and suppresses microtubule assembly dynamic. This results in cell cycle arrest at the G2/M phase and an induction of apoptosis.

Theaflavin digallate and lactic acid together could reduce herpes simplex virus transmission.

Trimethylamine N-oxide (TMAO) is a gut microbiota-dependent metabolite derived from dietary choline, betaine, and carnitine. It induces inflammation by activating the ROS/NLRP3 inflammasome and promotes fibroblast differentiation through the activation of the TGF-β/Smad2 signaling pathway. TMAO is commonly used to induce cardiac fibrosis models.

Dextran sulfate sodium salt (MW 36,000–50,000) is a medium molecular weight polyanionic dextran derivative with strong intestinal epithelial permeability. It is the most commonly used agent for inducing inflammatory bowel disease (IBD) models, effectively inducing both acute and chronic colitis. Its mechanism may involve macrophage dysfunction and gut microbiota dysbiosis. Due to its colonic epithelial toxicity, long-term use can also induce colorectal cancer models.

2-Hydroxy-4-methoxybenzoic acid (2-Hydroxy-p-anisic Acid) is a predicted metabolite generated by BioTransformer1 that is produced by the metabolism of 3-(2-hydroxy-4-methoxyphenyl)propanoic acid. It is generated by unspecified-gutmicro enzyme via a beta-oxidation-of-carbxoylic-acid reaction. This beta-oxidation-of-carbxoylic-acid occurs in human gut microbiota.

4-hydroxyphenylacetic acid (parahydroxy phenylacetate) is a major microbiota-derived metabolite of polyphenols. 4-hydroxyphenylacetic acid(p-Hydroxyphenylacetic acid) is involved in the antioxidative action. 4-hydroxyphenylacetic acid(p-Hydroxyphenylacetic acid) induces expression of Nrf2.

Trimethylamine N-oxide dihydrate (TMANO dihydrate) is a gut microbiota-dependent metabolite derived from dietary choline and other trimethylamine-containing nutrients. It induces inflammation by activating the ROS/NLRP3 inflammasome and promotes fibroblast differentiation and cardiac fibrosis via the TGF-β/Smad2 signaling pathway. TMANO dihydrate can be used to establish models of cardiac hypertrophy and cardiac fibrosis.

Terbuthylazine is a triazine herbicide and a selective acetolactate synthase (ALS) inhibitor, toxic to aquatic organisms, and capable of disrupting gut microbiota. Terbuthylazine induces significant damage to the jejunal barrier and mitochondrial quality control imbalance.

5-(3',4'-Dihydroxyphenyl)-γ-valerolactone is a metabolic byproduct of gut microbiota processing of (-)-Epicatechin. [5-(3',4'-Dihydroxyphenyl)-γ-valerolactone] exhibits antioxidant properties.

α-Glucosidase-IN-77 (Compound H7) is a non-competitive α-glucosidase inhibitor with an IC50 of 1.25 μM. It reduces blood glucose levels, improves glucose tolerance, regulates gut microbiota, and exhibits hepatoprotective effects in a mouse model of type 2 diabetes.

(3R,5R)-Octahydrocurcumin (Compound 7) is a metabolite of Curcumin produced by gut microbiota. It exhibits neuroprotective effects against Aβ25-35-induced cell damage in SH-SY5Y cells and possesses anti-inflammatory properties in LPS-stimulated BV-2 mouse microglia.

β-Glucuronidase-IN-3 (Compound 49) is a covalent allosteric inhibitor targeting β-glucuronidase. It exhibits potent inhibitory activity against Escherichia coli β-glucuronidase (EcGUS) with an IC50 of 12.9 nM. The compound exerts its inhibitory effect through reversible covalent modification of cysteine residues (Cys28, Cys443, and Cys197) on EcGUS. It is applicable in research on gut microbiota-related diseases, particularly in reducing the toxic side effects of Irinotecan and non-steroidal anti-inflammatory drugs (NSAIDs).

Urobilinogens comprise a mixture of bilirubin metabolites, including D-urobilinogen, L-urobilinogen (stercobilinogen), and i-urobilinogen (mesobilirubinogen). These compounds are produced from bilirubin by gut microbiota. In mice on a high-fat diet, the cecal concentrations of D-urobilinogen, L-urobilinogen, and i-urobilinogen are increased. Furthermore, elevated fecal levels of L-urobilinogen are inversely associated with reduced blood hemoglobin levels in patients with heterozygous β-thalassemia.

LK-60 is a potent inhibitor of DprE1. It effectively suppresses the proliferation of Mycobacterium tuberculosis. Additionally, LK-60 demonstrates good safety profiles for gut microbiota and human cells.

Lunularin is a naturally occurring bibenzyl compound widely distributed in liverworts (such as Conocephalum conicum) and is also a major gut microbiota-derived metabolite of resveratrol. Research indicates that Lunularin possesses significant antioxidant and anti-inflammatory properties and can selectively inhibit 11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1). Due to its role in regulating glucocorticoid activation and metabolic homeostasis, this molecule is of great interest in studies involving metabolic diseases, skin health, and neuroprotection.

3-(2,4-Dihydroxyphenyl)propanoic acid (Hydroumbellic acid) is a predicted metabolite generated by BioTransformer1 from the metabolism of 3-(2,4-dihydroxyphenyl)prop-2-enoic acid. It is produced by the abkar1 enzyme via a reduction-of-alpha-beta-unsaturated-compounds-pattern1 reaction in human gut microbiota.

Dihydroresveratrol (3,4',5-Trihydroxybibenzyl) is a major metabolite of resveratrol that is produced by animal-associated bacteria, including the gut microbiota. Dihydroresveratrol and dihydroresveratrol monosulfate are detectable in urine. The physiological effects of dihydroresveratrol have not been investigated.

Stachyose is an oligosaccharide that inhibits the proliferation of vancomycin-resistant enterococci.Stachyose regulates the intestinal microbiota and attenuates dextran sulfate sodium-induced acute colitis in mice.

ADL 08-0011 is an active metabolite of the μ-opioid receptor antagonist alvimopan. It is produced from alvimopan via amide hydrolysis by gut microbiota. ADL 08-0011 is a μ-opioid receptor antagonist (Ki = 0.25 nM). It is selective for μ-opioid receptors over κ- and δ-opioid receptors (Kis = 15.8 and 31.6 nM, respectively). ADL 08-0011 inhibits endomorphin 1-induced inhibition of electrically induced contraction of isolated guinea pig ileum (pA2 = 9.4). In vivo, ADL 08-0011 (0.03-1 mg/kg) reverses loperamide-induced delayed gastric emptying in a rat model of castor oil-induced diarrhea.

FFA3 Agonist 1, a potent agonist of the free fatty acid receptor 3 (FFA3), plays a crucial role in mediating the health-promoting effects of the intestinal microbiota through the activation of FFA3.

Phenyl sulfate is a gut microbiota-derived metabolite of tyrosine and a recognized uremic toxin. At a concentration of 30 µM, phenyl sulfate reduces the survival of differentiated human urinary podocyte-like epithelial cells (HUPECs), decreases intracellular glutathione (GSH) levels, and induces mitochondrial dysfunction. In a db/db mouse model of diabetes, phenyl sulfate administered at a dose of 50 mg/kg induces podocyte damage and albuminuria. Elevated plasma levels of phenyl sulfate are correlated with the progression of albuminuria in patients suffering from diabetic kidney disease, highlighting its role as a biomarker and potential therapeutic target.

4-Hydroxyphenylpropionylglycine, a metabolite derived from the conditionally essential amino acid tyrosine, is synthesized through a process involving aromatic amino acid aminotransferase and tyrosine aminotransferase activities, with subsequent modifications by gut microbiota and glycine conjugation. Additionally, it serves as a metabolite of the phenol phloretin.